In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest®: Results of a French multicentre study

International Journal of Antimicrobial Agents

Volumn 25, Issue 4, 2005, Pages 321-328

  Mallie M ^a   Bastide, J M ^a   Blancard, A ^b   Bonnin, A ^c   Bretagne, S ^d   Cambon, M ^e   Chandenier, J ^f   Chauveau, V ^g   Couprie, B ^h   Datry, A ⁱ   Feuilhade, M ^j   Grillot, R ^k   Guiguen, C ^l   Lavarde, V ^m   Letscher, V ⁿ   Linas, M D ^o   Michel, A ^p   Morin, O ^q   Paugam, A ^r   Piens, M A ^s   Raberin, H ^t   Tissot, E ^g   Toubas, D ^u   Wade, A ^g   more..

^a UNIV MONTPELLIER   (France)

^b TIMONE HOSPITAL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f CHU BRETONNEAU   (France)

^g PFIZER INC   (United States)

^h HÔPITAL SAINT ANDRÉ   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ Inst Parasitol et de Pathol Trop   (France)

^o CHU RANGUEIL   (France)

^p HÔPITAL SAINT JOSEPH   (France)

^q INSTITUT DE BIOLOGIE   (France)

^r Hôpital Cochin ^*  (France)

^s UNIVERSITÉ LYON 1   (France)

^t HÔPITAL NORD   (France)

^u HÔPITAL MAISON BLANCHE   (France)

more..

Author keywords

Amphotericin B; Aspergillus; Candida; Etest; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG POTENCY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 20144385089     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.11.010     Document Type: Article

References (38)

1. D. Ellis, D. Marriott, R.A. Hajjeh, D. Warnock, W. Meyer, and R. Barton Epidemiology: surveillance of fungal infections Med Mycol 38 Suppl 1 2000 173 182
2. D.W. Denning, K. Venkateswarlu, and K.L. Oakley Itraconazole resistance in Aspergillus fumigatus Antimicrob Agents Chemother 41 1997 1364 1368
3. J.H. Rex, M.G. Rinaldi, and M.A. Pfaller Resistance of Candida species to fluconazole Antimicrob Agents Chemother 39 1995 1 8
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS Document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
5. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 2nd ed. NCCLS Document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
6. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. Document M38-P. Wayne, PA: National Committee for Clinical Laboratory Standards, 1998.
7. S.C.A. Chen, M.L. O'Donnell, S. Gordon, and G.L. Gilbert Antifungal susceptibility testing using the E-test: comparison with the broth macrodilution technique J Antimicrob Chemother 37 1996 265 273
8. E. Chryssanthou, and M. Cuenca-Estrella Comparison of the antifungal susceptibility testing subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species J Clin Microbiol 40 2002 3841 3844
9. A.L. Colombo, F. Barchiesi, D.A. McGough, and M.G. Rinaldi Comparison of E-test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing J Clin Microbiol 33 1995 535 540
10. A. Espinel-Ingroff E test for antifungal susceptibility testing of yeasts Diagn Microbiol Infect Dis 19 1994 217 220
11. A. Espinel-Ingroff, M.A. Pfaller, M.E. Erwin, and R.N. Jones Interlaboratory evaluation of E test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using casitone agar and solidified RPMI 1640 medium with 2% glucose J Clin Microbiol 34 1996 848 852
12. A. Espinel-Ingroff In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens J Clin Microbiol 36 1998 198 202
13. F. Marco, M.A. Pfaller, S. Messer, and R.N. Jones In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp Antimicrob Agents Chemother 42 1998 161 163
14. J.R. Perfect, K.A. Marr, and T.J. Walsh Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 2003 1122 1231
15. T.J. Walsh, I. Lutsar, and T. Driscoll Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 2002 240 248
16. M. Ruhnke, A. Schmidt-Westhausen, and M. Trautmann In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection Antimicrob Agents Chemother 41 1997 575 577
17. M.J. Maxwell, S.A. Messer, and R.J. Hollis Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood J Clin Microbiol 41 2003 1087 1090
18. J.B. Pfaller, S.A. Messer, R.J. Hollis, D.K. Diekema, and M.A. Pfaller In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs J Clin Microbiol 41 2003 1126 1129
19. M.A. Pfaller, S.A. Messer, A. Houston, K. Mills, A. Bolmstrom, and R.N. Jones Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media J Clin Microbiol 38 2000 3715 3717
20. M.A. Pfaller, D.J. Diekema, S.A. Messer, L. Boyken, and R.J. Hollis Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program J Clin Microbiol 41 2003 1440 1446
21. M.C. Serrano, D. Morilla, and A. Valverde Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole J Clin Microbiol 41 2003 5270 5272
22. M.J. Matar, L. Ostrosky-Zeichner, V.L. Paetznick, J.R. Rodriguez, E. Chen, and J.H. Rex Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole Antimicrob Agents Chemother 47 2003 1647 1651
23. M.A. Pfaller, S.A. Messer, K. Mills, and A. Bolmström In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs J Clin Microbiol 38 2000 3359 3361
24. M.A. Pfaller, S.A. Messer, A. Bolmström, F.C. Odds, and J.H. Rex Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates J Clin Microbiol 34 1996 1691 1693
25. A.L. Barry, and S.D. Brown In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species Antimicrob Agents Chemother 40 1996 1948 1949
26. A. Koul, J. Vitullo, G. Reyes, and M. Ghannoum Effects of voriconazole on Candida glabrata in vitro J Antimicrob Chemother 44 1999 109 112
27. F. Marco, M.A. Pfaller, S.A. Messer, and R.N. Jones Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi Med Mycol 36 1998 433 436
28. M.A. Pfaller, S.A. Messer, R.J. Hollis, R.N. Jones, and D.J. Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp Antimicrob Agents Chemother 46 2002 1723 1727
29. J.M. Sabo, and S.M. Abdel-Rahman Voriconazole: a new triazole antifungal Ann Pharmacother 34 2003 1032 1043
30. A. Espinel-Ingroff Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi J Clin Microbiol 39 2001 1360 1367
31. A. Espinel-Ingroff, and A. Rezusta E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method J Clin Microbiol 40 2002 2101 2107
32. P.E. Verweij, D.T.A. Te Dorsthorst, A.J.M.M. Rijs, H.G. de Vries-Hospers, J.F.G.M. Meis The Dutch Interuniversity Working Party for Invasive Mycoses Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultures between 1945-1998 J Clin Microbiol 40 2002 2648 2650
33. M. Murphy, E.M. Bernard, T. Ishimaru, and D. Armstrong Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis Antimicrob Agents Chemother 41 1997 696 698
34. D.W. Denning, R. Ribaud, and N. Milpied Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 2002 563 571
35. R. Herbrecht, D.W. Denning, and T.F. Patterson Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
36. R. Ally, D. Schürmann, W. Kreisel The Esophageal Candidiasis Study Group A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients Clin Infect Dis 33 2001 1447 1454
37. T.J. Walsh, P. Pappas, and D.J. Winston Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
38. M. Cuenca-Estrella, T.M. Díaz-Guerra, E. Mellado, A. Monzón, and J.L. Rodríguez-Tudela Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain Eur J Clin Microbiol Infect Dis 18 1999 432 435